NRAS and synovial sarcoma: Our present results demonstrated a prosurvival role for drug-induced ERK activation in SS cells and provided evidence for a positive interaction between SAHA and the ERK pathway inhibitor trametinib in reducing cell proliferation and inducing apoptosis even in the presence of NRAS activating mutation.